Consistency over intensity: atorvastatin 40 mg plus ezetimibe 10 mg versus atorvastatin 80 mg in ACS patients: a comparative study of efficacy, tolerability, and cardiovascular outcomes

Atorvastatin 40 mg plus ezetimibe 10 mg demonstrated superior LDL-C reduction, improved tolerability, and fewer MACE compared to atorvastatin 80 mg monotherapy in ACS patients. These findings support the use of combination therapy as a viable starting alternative to atorvastatin 80 mg monotherapy following ACS, particularly in patients likely to have statin intolerance.